TerminatedNCT00299234
Atomoxetine for Children With Acquired Attentional Disorders Following Completion of Chemotherapy for ALL
Medication studyAges 6–18United StatesADHD
Understand this study
Who could participate?
Listed age limits: 6 years to 18 years.
- Listed locations
- NorfolkSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateJune 2006
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 1
- Sponsor
- Monarch Medical Research
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 6 Years to 18 Years
- Official registry ID
- NCT00299234
- Official title
Show the full official title
Atomoxetine for Children With Acquired Attentional Disorders Following Completion of Chemotherapy for Acute Lymphocytic Leukemia
Recruitment & locations
TerminatedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Norfolk
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Monarch Medical Research.
Does this study involve medication?
Yes. The study involves medication, including Atomoxetine.
Who can participate?
Listed age limits: 6 years to 18 years.
Is this study still recruiting?
The registry lists this study as terminated.
Want to explore more studies?
Explore studiesRelated studies
A Double-Blind Comparison of Naltrexone and Placebo in Adults With Attention Deficit Hyperactivity Disorder
A Phase 2 Randomized Double-Blind, Parallel, Adaptive-Design, Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR With NRCT-202XR Compared to NRCT-202XR Alone in Subjects With Attention-Deficit/Hyperactivity Disorder